Plastic cytotoxicity testing is an in vitro biocompatibility evaluation that determines whether polymeric materials release substances harmful to living cells, and it is a mandatory screening item under ISO 10993-5 and GB/T 16886.5 for medical device registration worldwide. By exposing cultured mammalian cells to plastic test samples or their extracts, accredited third-party laboratories can quantify cell viability and identify potential toxicity from monomers, plasticizers, stabilizers, and sterilization residues. This article explains the standards, sample types, test items, laboratory methods, evaluation criteria, and typical applications of cytotoxicity testing for plastic materials.
Technical Overview
Plastic cytotoxicity testing is an in vitro biological evaluation designed to assess whether a plastic material, or substances leaching from it, causes damage to living cells. Plastics used in medical devices, pharmaceutical packaging, and consumer products may contain residual monomers, oligomers, plasticizers, antioxidant additives, colorants, processing aids, catalyst residues, or sterilization by-products that can migrate out of the material and produce toxic effects at the cellular level.
The test is performed by culturing a mammalian cell line, most commonly L929 mouse fibroblast cells, in the presence of the test sample or an extract prepared from the sample. After a defined exposure period, cell health is evaluated through morphological observation, viability staining, or quantitative metabolic assays. The test is conducted in accordance with recognized standards, primarily ISO 10993-5 (Tests for in vitro cytotoxicity) and its Chinese equivalent GB/T 16886.5, with sample preparation governed by ISO 10993-12 and GB/T 16886.12. Related references include EN ISO 10993-5, USP General Chapter <87> (In Vitro Reactivity), ASTM F813, ASTM F895, and ASTM F619.
Cytotoxicity testing is generally the first and most fundamental step in the biological evaluation of any plastic medical device, because it is rapid, sensitive, cost-effective, and predictive of downstream biocompatibility outcomes. A material that fails the cytotoxicity test typically requires formulation or process modification before further biological testing is justified.
Testing Samples
Medical Device Plastics and Components
This category covers the widest range of submissions and includes catheters, syringe barrels and plungers, infusion and transfusion sets, IV connectors, luer fittings, wound dressings and adhesive backings, membrane filters, ventilator components, diagnostic consumables such as microplates and pipette tips, and device housings made from engineering polymers. Common materials include PVC, polyethylene, polypropylene, polystyrene, polycarbonate, polyurethane, ABS, PEEK, silicone elastomers, thermoplastic elastomers, and cyclic olefin copolymers.
Pharmaceutical Packaging Plastics
Direct contact packaging materials for drugs, including blister films, bottle bodies and closures, vial stoppers and seals, prefilled syringe components, and flexible infusion bags, are tested to demonstrate that leachables do not produce cellular toxicity. Evaluations frequently reference USP <87> for in vitro reactivity and may be integrated into extractables and leachables studies.
Food Contact and Cosmetic Packaging Plastics
Although food contact regulations emphasize chemical migration limits, cytotoxicity testing provides supplementary biological safety evidence for reusable containers, infant feeding products, drinking straws, closures, cosmetic bottles, cream jars, and pump dispensers, particularly for new polymers, recycled materials, or novel barrier coatings.
Raw Materials and Polymer Compounds
Resin producers, compounders, and masterbatch manufacturers submit pellets, granules, films, sheets, compression-molded plaques, or cured elastomer specimens to screen new formulations, evaluate alternative additives, qualify suppliers, or verify material consistency after process changes.
Testing Items
The scope of plastic cytotoxicity testing typically includes the following items, selected according to the intended use and physical form of the sample:
- Extract test (elution test): evaluation of the cytotoxicity of liquid extracts prepared from the plastic sample under standardized extraction conditions, suitable for almost all sample forms.
- Direct contact test: placement of the test specimen directly onto the cultured cell monolayer, suitable for flat materials, films, and dense solids where surface leachables and physical contact both matter.
- Indirect contact tests: agar overlay assay and filter diffusion assay, used for materials that would otherwise physically damage the cell layer or where diffusable toxicants must be evaluated through a barrier.
- Quantitative cell viability assays: MTT, XTT, CCK-8/WST-1, Alamar Blue, and neutral red uptake (NRU) assays that measure metabolic activity or lysosomal integrity as a percentage of the blank control.
- Morphological evaluation: microscopic grading of cell lysis, vacuolization, detachment, and membrane integrity using the ISO 10993-5 reactivity scale from grade 0 (none) to grade 4 (severe).
- Colony formation assay: a clonogenic endpoint measuring the ability of surviving cells to proliferate into colonies, offered as a confirmatory method in some laboratory schemes.
- Interference controls: blank extract absorbance checks and MTT direct-reduction controls for colored, turbid, or reducing samples that may bias spectrophotometric readings.
Testing Methods
Sample Preparation and Extraction
Sample preparation follows ISO 10993-12 and GB/T 16886.12. Test specimens are cut, cleaned, and sterilized in a manner representative of clinical use. Extraction is performed using the polar medium (e.g., serum-supplemented minimum essential medium or physiological saline) and, where required, a non-polar medium (e.g., sesame or cottonseed oil). Standard extraction conditions include 37°C for 72 hours, 50°C for 72 hours, 70°C for 24 hours, or 121°C for 1 hour, selected so that the extraction is exhaustive but does not degrade the polymer artificially. The extraction ratio is based on sample geometry, commonly 3 cm²/mL or 6 cm²/mL of surface area for flat materials and 0.1 to 0.2 g/mL for irregular solids.
MTT Colorimetric Assay
The MTT assay is the most widely used quantitative method. L929 cells are seeded in 96-well plates and allowed to form a monolayer. Cells are then exposed to serial dilutions of the test extract for approximately 24 hours, after which MTT reagent is added. Viable cells with functioning mitochondria reduce the yellow tetrazolium salt to purple formazan crystals, which are dissolved in an organic solvent and quantified by absorbance at approximately 570 nm. Cell viability is calculated relative to the blank extract control, and a viability of 70 percent or greater is classified as non-cytotoxic per ISO 10993-5:2009.
Neutral Red Uptake Assay
The neutral red uptake method measures the capacity of viable cells to incorporate and retain the dye in lysosomes. It is particularly useful as a complementary endpoint to MTT and is less affected by certain metabolic poisons, strengthening the overall reliability of the conclusion.
Direct Contact and Agar Overlay Methods
In the direct contact test, a sterile specimen is placed gently on the cell monolayer and incubated for 24 to 48 hours; cytotoxicity is scored by the zone of deformity, lysis, or detachment beneath and around the specimen. In the agar overlay method, an agar layer protects the cells while allowing diffusable toxicants to pass; a neutral red viability stain sharpens the visualization of the affected zone. Both methods report reactivity on the 0 to 4 grading scale.
Evaluation and Reporting
The final report states the cell line, extraction media and conditions, exposure duration, viability values for each extract concentration, reactivity grades, the appearance of cells and extracts, and a clear conclusion of cytotoxic or non-cytotoxic. Where a quantitative assay shows viability below 70 percent, dose-response data help identify the concentration at which 50 percent inhibition occurs, supporting root-cause investigation of the responsible formulation component.
Applications
Plastic cytotoxicity testing supports product development and regulatory compliance across multiple industries:
- Medical device registration and biological evaluation files, including submissions to regulatory authorities in China, the United States, and the European Union under the ISO 10993 series framework.
- Pharmaceutical packaging qualification per USP <87> and related pharmacopoeial requirements for plastic components and systems.
- Material screening during research and development, allowing rapid comparison of candidate polymers, additives, and masterbatches before tooling investment.
- Change control, covering raw material supplier changes, reformulation, new coloring pigments, or revised processing parameters.
- Sterilization validation support, comparing residual toxicity after ethylene oxide, gamma, e-beam, or steam sterilization cycles.
- Food contact and cosmetic packaging safety demonstration as supplementary biological evidence alongside migration testing.
- Stability studies and shelf-life justification for aged or accelerated-aged plastic products.
FAQ
What is the pass criterion for plastic cytotoxicity testing?
Under ISO 10993-5, a test sample is considered non-cytotoxic when the mean cell viability of the test extract is at least 70 percent of the blank control in a quantitative assay, or when the reactivity grade is 0 or meets the product-specific acceptance limit in qualitative assays such as direct contact or agar overlay.
Which cell line is used?
The L929 mouse fibroblast cell line is the most common choice and is specifically preferred under GB/T 16886.5. ISO 10993-5 also permits other established cell lines, such as V79 and BALB/c 3T3, provided their sensitivity is demonstrated and justified.
How much sample is required?
The required quantity depends on the extraction ratio and the number of conditions tested. As a practical guide, laboratories typically request finished products or material plaques providing 30 to 120 square centimeters of test surface, or 3 to 12 grams of pellets or irregular solids, together with retention samples.
How long does the test take?
The standard workflow, including extraction, cell exposure, and viability measurement, generally requires 7 to 14 working days. Complex studies involving multiple extraction conditions, dose-response dilution series, or repeat testing for confirmation may require additional time.
What is the difference between the extract test and the direct contact test?
The extract test evaluates only substances that leach from the plastic into a liquid medium and is applicable to virtually any sample shape. The direct contact test additionally captures effects of the material surface itself and is best suited to smooth, flat specimens that do not crush the cell monolayer. Accredited third-party laboratories select the most appropriate method based on the product's clinical contact mode.
Can cytotoxicity failure be investigated further?
Yes. When a sample fails, laboratories can perform extract dilution dose-response analysis, compare polar versus non-polar extraction media, evaluate individual formulation ingredients, or combine cytotoxicity data with chemical characterization for extractables and leachables to identify the causative substance and guide material improvement.